Brief: Outlook Therapeutics Announces LYTENAVA FDA Approval For Treatment Of Wet AMD
24/07/2026 19:43
BRIEF-Outlook Therapeutics Announces LYTENAVA FDA Approval For Treatment Of Wet AMD July 24 (Reuters) - Outlook Therapeutics Inc OTLK.O:
OUTLOOK THERAPEUTICS ANNOUNCES LYTENAVA™ FDA APPROVAL AS THE FIRST AND ONLY FDA-APPROVED OPHTHALMIC BEVACIZUMAB FOR THE TREATMENT OF WET AMD
OUTLOOK THERAPEUTICS - LYTENAVA ANTICIPATED TO HAVE 12 YEARS OF MARKET EXCLUSIVITY UNDER BPCIA
OUTLOOK THERAPEUTICS INC: ANTICIPATED 12 YEARS OF MARKET EXCLUSIVITY UNDER BIOLOGICS PRICE COMPETITION AND INNOVATION ACT
OUTLOOK THERAPEUTICS - LYTENAVA EXPECTED TO BE AVAILABLE TO U.S. PATIENTS BEFORE YEAR-END
Source text: ID:nGNX9QT15f
Further company coverage: OTLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce